SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-011470
Filing Date
2022-04-29
Accepted
2022-04-29 08:00:38
Documents
13
Period of Report
2022-04-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 42998
2 ex10-1.htm EX-10.1 395356
  Complete submission text file 0001493152-22-011470.txt   694547

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE avte-20220426.xsd EX-101.SCH 2965
4 XBRL LABEL FILE avte-20220426_lab.xml EX-101.LAB 34916
5 XBRL PRESENTATION FILE avte-20220426_pre.xml EX-101.PRE 22793
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3668
Mailing Address 200 BERKELEY STREET FLOOR 18 BOSTON MA 02116
Business Address 200 BERKELEY STREET FLOOR 18 BOSTON MA 02116 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

IRS No.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40544 | Film No.: 22870279
SIC: 2834 Pharmaceutical Preparations